Educational information only — not a diagnosis or treatment recommendation.
Content last checked: Jul 15, 2026·Sources & review
treatment · Prostate Cancer
Is active surveillance a reasonable option for prostate cancer?
Short answer
For selected lower-risk prostate cancers, active surveillance can defer treatment side effects while monitoring for change. Reasonableness depends on risk group, life expectancy, MRI/biopsy findings, and comfort with follow-up intensity.
Why patients ask this
Patients often fear undertreatment and need clarity on when surveillance is evidence-aligned versus when definitive therapy is favored.
Key factors to consider
- Risk classification and PSA kinetics
- MRI and biopsy findings
- Age and comorbidities
- Tolerance for uncertainty
- Follow-up access and adherence
Questions to ask your doctor
Bring these to your next visit to clarify the decision in front of you.
- What features put me in a surveillance-appropriate group?
- What exact triggers would end surveillance?
- How do side-effect profiles of treatment compare with my risk?
Before you leave
Your next step
You are at treatment. Do these three things next:
- Write down what is still unknown
- Ask which next result would change the plan
- List the questions you will bring to your next visit
Bring this question to your visit: “What features put me in a surveillance-appropriate group?”